The Nrf2 pathway as a potential therapeutic target for Huntington disease. A commentary on “Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide
improve the behavioral phenotype and brain pathology in a transgenic mouse model
of Huntington disease”

Carole Escartin; Emmanuel Brouillet

doi:10.1016/j.freeradbiomed.2010.04.009

Journal articles

The Nrf2 pathway as a potential therapeutic target for Huntington disease. A commentary on “Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington disease”

Carole Escartin ¹ Emmanuel Brouillet ^{1, *}

* Corresponding author

1 LMN - Laboratoire des Maladies Neurodégénératives - UMR 9199

MIRCEN - Service MIRCEN : DRF/JACOB, CNRS - Centre National de la Recherche Scientifique : UMR 9199

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Neurons and Cognition [q-bio.NC] / Neurobiology

Complete list of metadatas

https://hal-cea.archives-ouvertes.fr/cea-02168439
Contributor : Carole Escartin <>
Submitted on : Friday, June 28, 2019 - 4:45:12 PM
Last modification on : Friday, July 3, 2020 - 11:52:03 AM

The Nrf2 pathway as a potential therapeutic target for Huntington disease. A commentary on “Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington disease”

Identifiers

Collections

Citation

Export

Metrics

39

The Nrf2 pathway as a potential therapeutic target for Huntington disease. A commentary on “Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington disease”

Identifiers

Collections

Citation

Export

Share

Metrics

39